The Medicines Co’s experimental intravenous blood clot preventer Cangrelor, which is intended for use during angioplasty procedures, solidly outperformed commonly used Plavix in a pivotal late stage study, likely resurrecting the drug’s prospects. Deepak Bhatt, HMS professor of medicine at Brigham and Women’s Hospital and chief of cardiology at the VA Boston Health Care system, is a co-lead investigator of the study.
